Oral GLP‑1s cleared
The FDA approved Eli Lilly’s oral GLP‑1 orforglipron (branded Foundayo) and separately approved an oral semaglutide pill for weight loss, expanding pill options in the obesity‑drug class. The approvals come with safety warnings and common side effects noted, and retailers like Amazon Pharmacy are preparing same‑day delivery for some products while off‑brand GLP‑1 options remain widely available. (ajmc.com) (ajmc.com) (prismnews.com) (healio.com)
The U.S. Food and Drug Administration approved Eli Lilly’s once‑daily oral GLP‑1 pill Foundayo (orforglipron) for adults with obesity on April 1, 2026. (fda.gov) The agency granted the decision under the Commissioner’s National Priority Voucher pilot program, approving the drug 50 days after filing and 294 days before its original PDUFA date. (fda.gov) Separately, Novo Nordisk’s oral semaglutide pill (Wegovy) received FDA approval December 22, 2025, based on OASIS trial results showing mean weight loss in the mid‑teens at one year. (prnewswire.com) Taken together, the approvals expand the number of pill options in the GLP‑1 class that were previously dominated by injectables such as Wegovy and tirzepatide products. (prnewswire.com) Foundayo’s label carries a boxed warning about the risk of thyroid C‑cell tumors and lists common gastrointestinal adverse reactions—nausea, constipation, diarrhea and vomiting among the most frequent. (accessdata.fda.gov) The FDA and Eli Lilly say Foundayo is started at 0.8 mg once daily with stepwise titration up to as much as 17.2 mg, and the pill can be taken without regard to food. (fda.gov) Retail and distribution partners moved quickly: Amazon Pharmacy announced same‑day delivery for Foundayo in nearly 3,000 U.S. cities and towns, with plans to expand to roughly 4,500 locations by year end. (businesswire.com) Amazon’s announcement included pricing examples — as low as $1 per day with insurance or about $5 per day for cash pay after automatic manufacturer coupons — and Amazon quoted Tanvi Patel saying the service reduces barriers to access. (businesswire.com) Despite improved branded supply, non‑branded and compounded GLP‑1 products remain widely available on some direct‑to‑patient platforms even after regulators say national shortages have stabilized. (healio.com) Foundayo is now listed as available through LillyDirect, telehealth providers and U.S. retail pharmacies, and distributors including Amazon say shipments are beginning immediately. (medical.lilly.com)
